| Literature DB >> 36134045 |
Vaishali S Makwana1, Sejal G Bhadja1, Bhavesh M Songara1, Zalak R Patel1, Aniruddha P Vyas1.
Abstract
Introduction Topical medications are one of the most commonly used therapeutic agents in treating a wide spectrum of dermatological diseases. The misuse of topical medicines for inappropriate indications and an extended period may result in cutaneous adverse drug reactions (ADR). Aims We conducted this study to observe demographic parameters, commonly misused topical medicines, various clinical patterns of cutaneous ADR, and source of drug prescription among study participants. Materials and methods This cross-sectional observational study was conducted from October 2021 to May 2022 at the dermatology outpatient department (OPD) of a tertiary care center. All patients who presented with worsening pre-existing skin diseases or the development of skin disease after the topical application of some cream or ointment were included in the study with written informed consent. A detailed history was taken, and a clinical examination was done. Results We detected 200 cases (1.62%) of cutaneous ADR out of 12,346 OPD patients in the eight-month study period. The most common age group was 21-30 years (30%). Most of the patients had used topical medicines for fungal infections (76%). The most commonly used topical medication was a fixed drug combination (FDC) of steroid, antifungal, and antibacterial agents (40%). Tinea incognito (36%) was the most common cutaneous ADR noted. Conclusion This study shows that misuse of topical medications is rampant in our community because of their free and easy availability. There is an urgent requirement for strict regulations over the manufacturing, sales, and marketing of over-the-counter (OTC) topical medications to reduce the incidence of cutaneous ADR.Entities:
Keywords: cutaneous adverse drug reaction; fixed drug combination; over the counter cream; tinea incognito; triple combination
Year: 2022 PMID: 36134045 PMCID: PMC9482432 DOI: 10.7759/cureus.28139
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Demographic details of patients presenting with cutaneous adverse drug reactions following the application of topical medications
| Parameters | n=200 (%) |
| Most common Age group | |
| 21-30 years | 60 (30%) |
| Gender | |
| Male | 96 (48%) |
| Female | 104 (52%) |
| Education | |
| Illiterate | 61 (30.5%) |
| Literate | 139 (69.5%) |
| Occupation | |
| Student | 51 (25.5%) |
| Housewife | 64 (32%) |
| Manual worker | 63 (31.5%) |
| Office worker | 14 (7%) |
| Non-working (retired, children) | 8 (4%) |
| Residence | |
| Urban | 92 (46%) |
| Rural | 108 (54%) |
| Duration of usage | |
| < 1 month | 73 (36.5%) |
| 1-3 months | 98 (49%) |
| 3-6 months | 27 (13.5%) |
| 6-12 months | 2 (1%) |
Indications of using topical medications by the patients
| Indication | n= 200 (%) |
| Fungal infections (Dermatophytosis, Candidiasis, Pityriasis Versicolor) | 152 (76%) |
| Melasma | 23 (11.5%) |
| Pruritus | 7 (3.5%) |
| Viral infections (Wart, Molluscum Contagiosum) | 5 (2.5%) |
| Psoriasis | 4 (2%) |
| Acne | 4 (2%) |
| Bacterial infections (Pyoderma) | 2 (1%) |
| Eczema | 1 (0.5%) |
| Scabies | 1 (0.5%) |
| Burn | 1 (0.5%) |
Various types of topical medications implicated in reported cutaneous adverse drug reactions
| Topical medications | n =200(%) |
| Fixed dose combination - (Steroid + antibacterial + antifungal) | 80 (40%) |
| Clobetasol propionate 0.05% + Gentamicin sulphate 0.1% + Miconazole nitrate 2% | 25 |
| Clobetasol propionate 0.05% + Neomycin sulphate 0.5% + Miconazole nitrate 2% | 20 |
| Clobetasol propionate 0.05% + Neomycin sulphate 0.5% + Ketoconazole 2% | 13 |
| Clobetasol propionate 0.05% + Ofloxacin 0.75% + Ornidazole 1% + Itraconazole 1% | 9 |
| Beclomethasone dipropionate 0.025% + Neomycin sulphate 0.5% + Econazole nitrate 0.1% | 6 |
| Beclomethasone dipropionate 0.025% + Neomycin sulphate 0.5% + Miconazole nitrate 2% | 5 |
| Clobetasol propionate 0.05% + Ciprofloxacin hydrochloride 1% + Terbinafine hydrochloride 1% | 2 |
| Triple combination | 30 (15%) |
| Mometasone furoate 0.1% + Hydroquinone 2% + Tretinoin 0.025% | 30 |
| Steroid + antibacterial | 7 (3.5%) |
| Betamethasone dipropionate 0.05% + Gentamicin sulphate 0.1% | 7 |
| Steroid + antifungal | 18 (9%) |
| Beclomethasone dipropionate 0.025% + Clotrimazole 1% | 18 |
| Steroid | 3 (1.5%) |
| Clobetasol propionate 0.05% | 3 |
| Antifungal | 5 (2.5%) |
| Luliconazole 1% | 5 |
| Antibacterial | 2 (1%) |
| Neomycin sulfate 0.05% | 2 |
| Other over-the-counter products | 55 (27.5%) |
| Sapat lotion, Derobin, salicylic acid, coal tar, | 55 |
Figure 1Tinea incognito
Figure 2Irritant contact dermatitis
Clinical patterns and the most common causative agents for cutaneous adverse drug reactions
| Cutaneous adverse drug reactions | n=200 (%) | Agents (Most common) |
| Tinea incognito | 72 (36%) | Fixed drug combination |
| Irritant contact dermatitis | 25 (12.5%) | Sapat lotion |
| Eczematous changes | 23 (11.5%) | Parasmani Malam |
| Striae rubra | 19 (9.5%) | Fixed drug combination |
| Hyperpigmentation | 18 (9%) | Fixed drug combination |
| Acneiform eruption | 16 (8%) | Triple combination |
| Telangiectasia | 9 (4.5%) | Triple combination |
| Secondary bacterial infection | 4 (2%) | Fixed drug combination |
| Chemical burn | 4 (2%) | Derobin cream |
| Hypertrichosis | 3 (1.5%) | Triple combination |
| Photosensitivity | 3 (1.5%) | Parasmani Malam |
| Hypopigmentation | 3 (1.5%) | Triple combination |
| Necrotic change | 1 (0.5%) | Zalim Malam |
Sources of topical medications prescription
| Sources | n =200(%) |
| Pharmacist | 86 (43%) |
| Self-medication | 59 (29.5%) |
| Non dermatologist doctor | 36 (18%) |
| Relative | 16 (8%) |
| Dermatologist | 3 (1.5%) |
Comparison of data of present study with published studies
ADR: adverse drug reaction; n: number of patients
| Our Study | Birudala et al. [ | Dey et al. [ | Swaroop et al. [ | Meena et al. [ | Dabas et al. [ | |
| Year | 2021-2022 | 2017-2018 | 2010-2011 | 2018-2019 | 2015-2016 | - |
| Study period | 8 months | 1 year | 1 year | 1 year | 1 year | - |
| Total number of patients (n) | 200 | 453 | 379 | 100 | 370 | 100 |
| Most common age group (in years) | 21-30 (30%) | 21-30 (50.3%) | 20-29 (37.73%) | 21-30 (35%) | 11-20 (39.73%) | 19-45 (74%) |
| Gender | ||||||
| Male | 48% | 35.76% | 21.11% | 28% | 62.70% | 75% |
| Female | 52% | 64.24% | 78.89% | 72% | 37.3% | 25% |
| Source of drug (Most common) | Pharmacist (43%) | - | Pharmacist (35.36%) | Friends (46%) | Pharmacist (34.86%) | Pharmacist (30.88%) |
| Most common Indication of use | Fungal infection (76%) | Acne (39.7%) | Lightening of skin (50.39%) | Acne (35%) | Dermatophytosis (52.43%) | Tinea cruris (44%) |
| Duration of use (Most common) | 1-3 months (49%) | - | <1 year (69.39%) | >1 year (29%) | 1 week-1 month (48.91%) | - |
| Most common Adverse effect | Tinea incognito (36%) | Acneiform eruption (51.6%) | Facial acne (37.99%) | Acneiform eruption (45.2%) | Tinea incognito (49.46%) | Burning sensation (44.18%) |
| Most common Topical medication | Antifungal+ antibacterial+ steroid (40%) | Clobetasol propionate (41.1%) | Antifungal+ antibacterial+ steroid (39.84%) | Betamethasone valerate (32%) | Clobetasol propionate (44.32%) | Steroid based preparation (clobetasol propionate) (40%) |
| Proportion of cutaneous ADR | 1.62% | - | 5.63% | - | 0.43% | - |
Figure 3Various topical medicines misused by patients
Figure 4Striae rubra
Figure 5Acneiform eruption
Figure 6Necrotic change